At Pulmatrix, we are developing innovative inhaled therapies to address serious pulmonary disease using our clinically validated, proprietary iSPERSE technology. Leveraging the unique capabilities of iSPERSE to dramatically advance inhalation technology, we can create new therapies to improve patient outcomes. Our pipeline of inhaled therapies rrepresents innovative, first-in-class products. Our proprietary pipeline of novel, ...
At Pulmatrix, we are developing innovative inhaled therapies to address serious pulmonary disease using our clinically validated, proprietary iSPERSE technology. Leveraging the unique capabilities of iSPERSE to dramatically advance inhalation technology, we can create new therapies to improve patient outcomes. Our pipeline of inhaled therapies rrepresents innovative, first-in-class products. Our proprietary pipeline of novel, therapies for respiratory diseases is led by PUR1900, PUR1800 and PUR5700. PUR1900 is an inhaled anti-infective to treat ABPA in severe asthmatics and cystic fibrosis patients.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.